Back to top
more

Tandem Diabetes Care (TNDM)

(Delayed Data from NSDQ)

$15.40 USD

15.40
1,385,256

-0.18 (-1.16%)

Updated Aug 1, 2025 04:00 PM ET

After-Market: $15.39 -0.01 (-0.06%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 36% (158 out of 246)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Zacks.com featured highlights include: Synaptics, MagnaChip Semiconductor, Tandem Diabetes Care and International Money Express

by Zacks Equity Research

Zacks.com featured highlights include: Synaptics, MagnaChip Semiconductor, Tandem Diabetes Care and International Money Express

Zacks Equity Research

Moving Average Crossover Alert: Tandem Diabetes Care

by Zacks Equity Research

Tandem Diabetes Care, Inc. (TNDM) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

Zacks Equity Research

Check 4 Best Liquid Bets to Power Your Portfolio

by Zacks Equity Research

Four top-ranked liquid stocks that investors can bank on for fat returns.

Zacks Equity Research

What's in Store for Thermo Fisher (TMO) in Q4 Earnings?

by Zacks Equity Research

Strength in segments is expected to get reflected in Thermo Fisher's (TMO) fourth-quarter and 2019 top-line numbers.

Zacks Equity Research

Can Critical Care Aid Edwards Lifesciences (EW) Q4 Earnings?

by Zacks Equity Research

Robust customer adoption of the HemoSphere all-in-one monitoring platform is likely to have driven Edwards Lifesciences' (EW) Q4 revenues.

Zacks Equity Research

Can Sequencing Products Aid Illumina (ILMN) in Q4 Earnings?

by Zacks Equity Research

Illumina (ILMN) is upbeat about fourth-quarter and fiscal 2019 results after a strong third-quarter performance.

Zacks Equity Research

Will New Buyouts Aid Quest Diagnostics (DGX) Q4 Earnings?

by Zacks Equity Research

Quest Diagnostics' (DGX) acquisition of Clinical Laboratory Services of Boston Clinical Laboratories is expected to have been accretive to its Q4 earnings.

Zacks Equity Research

Moving Average Crossover Alert: Tandem Diabetes Care

by Zacks Equity Research

Tandem Diabetes Care, Inc. (TNDM) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

Zacks Equity Research

Will Segmental Growth Aid Hologic (HOLX) in Q1 Earnings?

by Zacks Equity Research

Strength in segmental businesses is likely to have aided Hologic's (HOLX) performance in first-quarter fiscal 2020.

Zacks Equity Research

Can Abbott (ABT) Q4 Earnings Ride on Growth in All Lines?

by Zacks Equity Research

Abbott's (ABT) imminent quarterly results are expected to reflect a solid performance by the Established Pharmaceuticals Division (EPD) business alike the last reported quarter.

Sriparna Ghosal headshot

Diabetes Management Gains FDA Attention: 3 Stocks in Focus

by Sriparna Ghosal

The FDA recently authorized diabetes care companies to start pairing their medical devices for diabetes management, by combining insulin pumps and glucose monitors.

Zacks Equity Research

Strong Pipeline Aids Tandem Diabetes Despite Stiff Rivalry

by Zacks Equity Research

Tandem Diabetes' (TNDM) products under development comprise AID systems, a next-generation hardware platform and connected (mobile) health offerings.

Trina Mukherjee headshot

6 MedTech Stocks That are Set to Beat the Market in 2020

by Trina Mukherjee

Banking on the three key trends, we zero in on six MedTech stocks that are likely to deliver stellar performance in 2020.

Zacks Equity Research

Tandem Diabetes Sees Hammer Chart Pattern: Time to Buy?

by Zacks Equity Research

Tandem Diabetes Care has been struggling lately, but the selling pressure may be coming to an end soon.

Zacks Equity Research

Tandem Diabetes Gets FDA Nod for t:slim X2 Insulin Pump

by Zacks Equity Research

The FDA nod for Tandem Diabetes' (TNDM) t:slim X2 insulin pump with Control-IQ will speed up its pump shipments within the United States and grow its clientele.

Trina Mukherjee headshot

Digital Diabetes Management Gains Momentum: 3 Stocks in Focus

by Trina Mukherjee

With digital diabetes management space rapidly gaining momentum, patients with diabetes can look forward to better and improved outcomes.

Zacks Equity Research

Here's Why You Should Buy Tandem Diabetes (TNDM) Stock Now

by Zacks Equity Research

Investor confidence in Tandem Diabetes (TNDM) stock is at a high, thanks to solid prospects.

Zacks Equity Research

Will Tandem Diabetes Continue to Surge Higher?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor in Tandem Diabetes Care.

Zacks Equity Research

Tandem Diabetes Gets Canadian Nod for t:slim X2 Insulin Pump

by Zacks Equity Research

This regulatory clearance is expected to accelerate Tandem Diabetes' (TNDM) global pump shipments and expand its customer base.

Zacks Equity Research

Tandem Diabetes (TNDM) Q3 Loss Narrows Y/Y, Sales Improve

by Zacks Equity Research

Tandem Diabetes (TNDM) exhibits a robust performance in the third quarter of 2019, fueled by strong domestic demand.

Zacks Equity Research

AmerisourceBergen (ABC) to Post Q4 Earnings: What's in Store?

by Zacks Equity Research

AmerisourceBergen's (ABC) Q4 earnings are likely to reflect the better-than-expected performance at Pharmaceutical Distribution and higher revenues.

Zacks Equity Research

DexCom (DXCM) to Report Q3 Earnings: What's in the Offing?

by Zacks Equity Research

DexCom's (DXCM) Q3 earnings is likely to reflect top-line growth and rising global awareness of the company's real-time CGM.

Zacks Equity Research

What's in Store for Tandem Diabetes' (TNDM) Q3 Earnings?

by Zacks Equity Research

Growth in t:slim X2 insulin pump sales is expected to get reflected in Tandem Diabetes' (TNDM) upcoming quarterly results.

Zacks Equity Research

Tandem (TNDM) Catches Eye: Stock Jumps 9.5%

by Zacks Equity Research

Tandem (TNDM) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.

Zacks Equity Research

Tandem Rides on Strong t:slim X2 Rollout Amid Stiff Rivalry

by Zacks Equity Research

Tandem Diabetes (TNDM) gains on strong domestic sales along with a solid international rollout of the t:slim X2 insulin pump.